This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GEMP vs. LXRX, CLYM, SLS, RANI, VTGN, ADAG, ANL, AVTX, VERU, and CLSDShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Lexicon Pharmaceuticals (LXRX), Climb Bio (CLYM), SELLAS Life Sciences Group (SLS), Rani Therapeutics (RANI), Vistagen Therapeutics (VTGN), Adagene (ADAG), Adlai Nortye (ANL), Avalo Therapeutics (AVTX), Veru (VERU), and Clearside Biomedical (CLSD). These companies are all part of the "medical" sector. Gemphire Therapeutics vs. Lexicon Pharmaceuticals Climb Bio SELLAS Life Sciences Group Rani Therapeutics Vistagen Therapeutics Adagene Adlai Nortye Avalo Therapeutics Veru Clearside Biomedical Lexicon Pharmaceuticals (NASDAQ:LXRX) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends. Do analysts rate LXRX or GEMP? Lexicon Pharmaceuticals presently has a consensus price target of $3.67, indicating a potential upside of 620.37%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Lexicon Pharmaceuticals is more favorable than Gemphire Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexicon Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Gemphire Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation and earnings, LXRX or GEMP? Gemphire Therapeutics has lower revenue, but higher earnings than Lexicon Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexicon Pharmaceuticals$31.08M4.03-$177.12M-$0.64-0.80Gemphire TherapeuticsN/AN/A-$23.64MN/AN/A Does the media prefer LXRX or GEMP? In the previous week, Lexicon Pharmaceuticals had 21 more articles in the media than Gemphire Therapeutics. MarketBeat recorded 21 mentions for Lexicon Pharmaceuticals and 0 mentions for Gemphire Therapeutics. Lexicon Pharmaceuticals' average media sentiment score of 0.61 beat Gemphire Therapeutics' score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Lexicon Pharmaceuticals Positive Gemphire Therapeutics Neutral Which has more risk and volatility, LXRX or GEMP? Lexicon Pharmaceuticals has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 2.82, indicating that its stock price is 182% more volatile than the S&P 500. Does the MarketBeat Community believe in LXRX or GEMP? Lexicon Pharmaceuticals received 195 more outperform votes than Gemphire Therapeutics when rated by MarketBeat users. However, 69.98% of users gave Gemphire Therapeutics an outperform vote while only 64.28% of users gave Lexicon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformLexicon PharmaceuticalsOutperform Votes48464.28% Underperform Votes26935.72% Gemphire TherapeuticsOutperform Votes28969.98% Underperform Votes12430.02% Is LXRX or GEMP more profitable? Gemphire Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -4,109.41%. Lexicon Pharmaceuticals' return on equity of -107.38% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lexicon Pharmaceuticals-4,109.41% -107.38% -64.09% Gemphire Therapeutics N/A -419.70%-173.05% Do institutionals & insiders believe in LXRX or GEMP? 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.5% of Gemphire Therapeutics shares are owned by institutional investors. 6.8% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 22.7% of Gemphire Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryLexicon Pharmaceuticals beats Gemphire Therapeutics on 10 of the 15 factors compared between the two stocks. Remove Ads Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.42M$6.76B$5.56B$7.88BDividend YieldN/A2.81%5.35%4.04%P/E RatioN/A7.2123.5018.75Price / SalesN/A203.71369.0989.54Price / CashN/A65.6738.1634.64Price / Book2.926.106.684.17Net Income-$23.64M$142.11M$3.20B$247.10M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$1.58+2.3%N/A-62.3%$23.42MN/A0.009Gap UpLXRXLexicon Pharmaceuticals3.3118 of 5 stars$0.37+0.6%$3.67+903.5%-79.6%$89.98M$31.08M-0.49140Short Interest ↓Gap DownCLYMClimb Bio2.9891 of 5 stars$1.32+1.5%$10.00+657.6%N/A$87.39MN/A-0.629SLSSELLAS Life Sciences Group0.0802 of 5 stars$1.23+2.5%N/A+1.9%$86.57M$1M-1.7810RANIRani Therapeutics2.7477 of 5 stars$1.47-5.2%$12.33+739.0%-60.7%$84.22MN/A-1.39110Earnings ReportNews CoverageVTGNVistagen Therapeutics2.0592 of 5 stars$2.91+4.3%N/A-56.7%$83.99M$698,000.00-1.9740Positive NewsADAGAdagene1.5273 of 5 stars$1.77+5.0%$8.00+352.0%-42.0%$83.39M$815,746.000.00260Gap DownHigh Trading VolumeANLAdlai Nortye2.511 of 5 stars$2.30+4.1%$9.00+291.3%-77.2%$81.55M$5M0.00127Gap UpAVTXAvalo Therapeutics3.6432 of 5 stars$7.63-0.4%$35.33+363.1%-61.7%$79.31M$820,000.000.0040VERUVeru1.4964 of 5 stars$0.53+3.5%$4.00+647.8%-15.8%$78.30M$16.89M-2.06230CLSDClearside Biomedical2.3259 of 5 stars$1.03+2.5%$5.75+458.3%-42.6%$78.12M$7.70M-2.2930Earnings ReportAnalyst ForecastNews Coverage Remove Ads Related Companies and Tools Related Companies Lexicon Pharmaceuticals Competitors Climb Bio Competitors SELLAS Life Sciences Group Competitors Rani Therapeutics Competitors Vistagen Therapeutics Competitors Adagene Competitors Adlai Nortye Competitors Avalo Therapeutics Competitors Veru Competitors Clearside Biomedical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GEMP) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
